Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 164.32 -2.17% -3.65
SAGE closed down 2.17 percent on Monday, May 20, 2019, on 1.23 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Down
See historical SAGE trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.56%
Fell Below 50 DMA Bearish 0.56%
Expansion Pivot Sell Setup Bearish Swing Setup 0.56%
Bollinger Band Squeeze Range Contraction 0.56%
BB Squeeze + Lower Band Touch Range Contraction 0.56%
Lower Bollinger Band Touch Weakness 0.56%
20 DMA Support Bullish -2.17%
Bollinger Band Squeeze Range Contraction -2.17%
Multiple of Ten Bearish Other -2.17%
Bollinger Band Squeeze Range Contraction -3.52%

Older signals for SAGE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Physical Sciences Drugs Antidepressants Gabaa Receptor Positive Allosteric Modulators Adjunctive Therapy Anticonvulsants Neurosteroids
Is SAGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 177.05
52 Week Low 79.88
Average Volume 468,586
200-Day Moving Average 140.5165
50-Day Moving Average 163.8804
20-Day Moving Average 167.3595
10-Day Moving Average 167.382
Average True Range 5.2358
ADX 13.98
+DI 19.0174
-DI 23.8067
Chandelier Exit (Long, 3 ATRs ) 156.8315
Chandelier Exit (Short, 3 ATRs ) 170.3774
Upper Bollinger Band 171.8269
Lower Bollinger Band 162.8921
Percent B (%b) 0.16
BandWidth 5.338687
MACD Line 0.8091
MACD Signal Line 1.3373
MACD Histogram -0.5281
Fundamentals Value
Market Cap 6.14 Billion
Num Shares 37.4 Million
EPS -6.09
Price-to-Earnings (P/E) Ratio -26.98
Price-to-Sales 0.00
Price-to-Book 8.73
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 172.68
Resistance 3 (R3) 172.95 170.44 171.28
Resistance 2 (R2) 170.44 168.31 170.30 170.82
Resistance 1 (R1) 167.38 167.00 166.13 167.11 170.35
Pivot Point 164.87 164.87 164.24 164.73 164.87
Support 1 (S1) 161.81 162.74 160.56 161.54 158.29
Support 2 (S2) 159.30 161.43 159.16 157.82
Support 3 (S3) 156.24 159.30 157.36
Support 4 (S4) 155.97